Pluri Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Pluri Inc. (PLUR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $3.62 million for the 9-month period ending 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2021-05-06
- Pluri Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-09-30 was -$1.64M.
- Pluri Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-09-30 was -$512.00K.
- Pluri Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-09-30 was -$298.00K, a 102.31% decline year-over-year.
- Pluri Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2017-09-30 was $12.89M.
- Pluri Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $4.04M.
- Pluri Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was -$4.70M, a 211.35% decline from fiscal 2018.
- Pluri Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was $4.22M.
- Pluri Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2017 was -$1.46M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $3.62M 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | -$929.00K 10-Q · filed 2021-02-08 | ||||
| 2020-09-30 | -$1.64M 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $4.04M 10-K · filed 2020-09-10 | ||||
| 2020-03-31 | $2.65M 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $3.08M 10-Q · filed 2021-02-08 | ||||
| 2019-09-30 | -$512.00K 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | -$4.70M 10-K · filed 2020-09-10 | ||||
| 2019-03-31 | $730.00K 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | -$1.80M 10-Q · filed 2020-02-06 | ||||
| 2018-09-30 | -$298.00K 10-Q · filed 2019-11-07 | $9.21M 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $4.22M 10-K · filed 2020-09-10 | ||||
| 2018-03-31 | $1.92M 10-Q · filed 2019-05-06 | ||||
| 2017-09-30 | $12.89M 10-Q · filed 2018-11-07 | ||||
| 2017-06-30 | -$1.46M 10-K · filed 2019-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |